D. E. Shaw & Co., Inc. Atai Life Sciences N.V. Transaction History

D. E. Shaw & Co., Inc.

$125 Billion
Q2 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 695,031 shares of ATAI stock, worth $4.46 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

695,031

Previous 993,361 30.03%

Holding current value

$4.46 Million

Previous $1.35 Million 12.74%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$1.21 - $2.49 $360,979 - $742,841	-298,330 Reduced 30.03%	695,031 $1.52 Million
Q1 2025 May 15, 2025	BUY	$1.33 - $2.55 $1.3 Million - $2.49 Million	978,327 Added 6507.43%	993,361 $1.35 Million
Q4 2024 Feb 14, 2025	BUY	$1.06 - $1.78 $15,936 - $26,760	15,034 New	15,034 $19,000
Q4 2023 Feb 14, 2024	BUY	$1.04 - $1.55 $112,494 - $167,660	108,168 New	108,168 $152,000
Q4 2022 Feb 14, 2023	SELL	$2.38 - $3.55 $210,089 - $313,369	-88,273 Reduced 83.78%	17,090 $45,000
Q3 2022 Nov 14, 2022	SELL	$3.14 - $4.87 $902,982 - $1.4 Million	-287,574 Reduced 73.19%	105,363 $349,000
Q2 2022 Aug 15, 2022	BUY	$3.03 - $5.32 $523,268 - $918,742	172,696 Added 78.41%	392,937 $1.43 Million
Q1 2022 May 16, 2022	BUY	$4.66 - $7.66 $129,198 - $212,373	27,725 Added 14.4%	220,241 $1.12 Million
Q4 2021 Feb 14, 2022	BUY	$6.82 - $17.8 $1.31 Million - $3.43 Million	192,516 New	192,516 $1.47 Million

Others Institutions Holding ATAI

# of Institutions

111

Shares Held

31.2M

Call Options Held

494K

Put Options Held

315K

View Full List

About ATAI Life Sciences N.V.

Ticker ATAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 165,875,008
Market Cap $1.06B
Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...

More about ATAI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account